GMAB Genmab

  1. Stocks
  2. Healthcare
  3. NASDAQ: GMAB

Price (delayed)

$25.27

Market cap

$16.23B

P/E Ratio

19

Dividend/share

N/A

EPS

$1.33

Enterprise value

$20.06B

?
Relative Growth: Rel. Growth: 76
Relative Strength: Rel. Strength: 35
Relative Valuation: Rel. Valuation: 52
Relative Profitability: Rel. Profitability: 87

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with ...

Highlights
Genmab's revenue has increased by 21% YoY and by 4.9% QoQ
The company's gross profit rose by 18% YoY and by 4.5% QoQ
The quick ratio has dropped by 60% year-on-year but it is up by 7% since the previous quarter
GMAB's price to earnings (P/E) is 44% lower than its 5-year quarterly average of 34.2 but 20% higher than its last 4 quarters average of 15.8
The net income has contracted by 28% YoY and by 15% from the previous quarter
The EPS has contracted by 25% YoY and by 14% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.genmab.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of GMAB

GMAB stock price

How has the Genmab stock price performed over time
Intraday
-0.47%
1 week
0.12%
1 month
-4.17%
1 year
17.21%
YTD
-17.95%
QTD
-5.81%

Financial performance

How have Genmab's revenue and profit performed over time
Revenue
$3.9B
Gross profit
$3.64B
Operating income
$1.06B
Net income
$821M
Gross margin
93.3%
Net margin
21%
Genmab's net margin has decreased by 40% YoY and by 19% from the previous quarter
The net income has contracted by 28% YoY and by 15% from the previous quarter
Genmab's revenue has increased by 21% YoY and by 4.9% QoQ
The company's gross profit rose by 18% YoY and by 4.5% QoQ

Price vs fundamentals

How does GMAB's price correlate with its fundamentals

Growth

What is Genmab's growth rate over time

Valuation

What is Genmab stock price valuation
GMAB P/E details
P/E
19
P/B
2.86
P/S
4.16
EV/EBIT
14.22
EV/EBITDA
13.42
EV/Sales
5.14
GMAB's price to earnings (P/E) is 44% lower than its 5-year quarterly average of 34.2 but 20% higher than its last 4 quarters average of 15.8
The EPS has contracted by 25% YoY and by 14% from the previous quarter
The P/B is 46% below the 5-year quarterly average of 5.3 and 8% below the last 4 quarters average of 3.1
The equity has grown by 7% YoY but it has contracted by 2.8% from the previous quarter
The P/S is 63% below the 5-year quarterly average of 11.1 and 13% below the last 4 quarters average of 4.8
Genmab's revenue has increased by 21% YoY and by 4.9% QoQ

Efficiency

How efficient is Genmab business performance
The ROA has plunged by 55% YoY and by 27% from the previous quarter
Genmab's return on invested capital has shrunk by 52% YoY and by 24% QoQ
Genmab's ROE has decreased by 39% YoY and by 17% from the previous quarter
The ROS has contracted by 28% YoY and by 9% from the previous quarter

Dividends

What is GMAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GMAB.

Financial health

How did Genmab financials performed over time
The total assets is 85% greater than the total liabilities
The total assets has surged by 88% year-on-year but it has declined by 3.9% since the previous quarter
The quick ratio has dropped by 60% year-on-year but it is up by 7% since the previous quarter
Genmab's debt is 6% less than its equity
The equity has grown by 7% YoY but it has contracted by 2.8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.